Top

Published in:

Open Access 01-04-2021 | Neurological Update

Neurological updates: neurological complications of CAR-T therapy

Authors: Emma C. Tallantyre, Nia A. Evans, Jack Parry-Jones, Matt P. G. Morgan, Ceri H. Jones, Wendy Ingram

Published in: Journal of Neurology | Issue 4/2021

Abstract

Chimeric antigen receptor (CAR)-expressing T cells now offer an effective treatment option for people with previously refractory B cell malignancies and are under development for a wide range of other tumours. However, neurological toxicity is a common complication of CAR-T cell therapy, seen in over 50% of recipients in some cohorts. Since 2018, the term immune effector cell-associated neurotoxicity syndrome (ICANS) has been used to describe and grade neurotoxicity seen after CAR-T cells and other similar therapies. ICANS following CAR-T therapy is usually self-limiting but can necessitate admission to the intensive care unit and is rarely fatal. As CAR-T therapies enter routine clinical practice, it is important for neurologists to be aware of the nature of neurological complications. Here, we summarise the clinical manifestations, mechanisms, investigations and recommended treatment of CAR-T-related neurotoxicity, focusing on the licensed CD19 products.

Locke FL, Jacobson CA, Miklos DB et al (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol 20:31–42. https://doi.org/10.1016/S1470-2045(18)30864-7.Long-termCrossRefPubMed

Neelapu S, Locke F, Bartlett N et al (2017) Axicabtagene ciloleucel CAR T cell therapy in refractory large B cell lymphoma. N Engl J Med 377:2531–2544. https://doi.org/10.1056/NEJMoa1707447CrossRefPubMedPubMedCentral

Frey NV (2019) Chimeric antigen receptor T cells for acute lymphoblastic leukemia. Am J Hematol 94:S24–S27. https://doi.org/10.1002/ajh.25442CrossRefPubMed

Vitale C, Strati P (2020) CAR T cell therapy for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia: clinical trials and real-world experiences. Front Oncol 10:849. https://doi.org/10.3389/fonc.2020.00849CrossRefPubMedPubMedCentral

Lee DW, Santomasso BD, Locke FL et al (2019) Biology of blood and marrow transplantation ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25:625–638. https://doi.org/10.1016/j.bbmt.2018.12.758CrossRefPubMed

Moreno Cortes EF, Stein CK, Lengerke Diaz PA et al (2019) Chimeric antigen receptor T cell therapy pipeline at a glance: a retrospective and systematic analysis from clinicaltrials. Gov Blood 134:5629CrossRef

Brudno JN, Kochenderfer JN (2019) Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev 34:45–55. https://doi.org/10.1016/j.blre.2018.11.002.RecentCrossRefPubMed

Rubin DB, Danish HH, Ali AB et al (2019) Neurological toxicities associated with chimeric antigen receptor T cell therapy. Brain 142:1334–1348. https://doi.org/10.1093/brain/awz053CrossRefPubMed

Brudno JN, Kochenderfer JN (2016) Toxicities of chimeric antigen receptor T cells: recognition and management. Adv Cell-Based Immune TherHematol 127:3321–3330. https://doi.org/10.1182/blood-2016-04-703751.CARCrossRef

10.

Gust J, Taraseviciute A, Turtle CJ (2018) Neurotoxicity associated with CD19—targeted CAR—T cell therapies. CNS Drugs 32:1091–1101. https://doi.org/10.1007/s40263-018-0582-9CrossRefPubMedPubMedCentral

11.

Gust J, Hay KA, Li D et al (2017) Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 7:1404–1419. https://doi.org/10.1158/2159-8290.CD-17-0698.EndothelialCrossRefPubMedPubMedCentral

12.

Neelapu SS, Tummala S, Kebriael P et al (2018) Chimeric antigen receptor T cell therapy—assessment and management of toxicities. Nat Rev Clin Oncol 15:47–62. https://doi.org/10.1038/nrclinonc.2017.148.ChimericCrossRefPubMed

13.

Santomasso BD, Park JH, Salloum D et al (2018) Clinical and biological correlates of neurotoxicity associated with CAR T cell therapy in patients with B cell acute lymphoblastic leukemia. Cancer Discov 8:958–971. https://doi.org/10.1158/2159-8290.CD-17-1319CrossRefPubMedPubMedCentral

14.

Gust J, Finney OC, Li D et al (2019) Glial injury in neurotoxicity after pediatricCD19-directed chimeric antigen receptor T cell therapy. Ann Neurol 86:42–54. https://doi.org/10.1002/ana.25502CrossRefPubMed

15.

Papadouli I, Mueller-Berghaus J, Beuneu C et al (2020) EMA review of axicabtagene ciloleucel (Yescarta ) for the treatment of diffuse large B cell lymphoma. Oncologist 25:1–9. https://doi.org/10.1634/theoncologist.2019-0646CrossRef

16.

Hunter BD, Jacobson CA (2019) Commentary CAR T cell associated neurotoxicity : mechanisms, clinicopathologic correlates, and future directions. J Natl Cancer Inst 111:646–654. https://doi.org/10.1093/jnci/djz017CrossRefPubMed

17.

Maude S, Laetsch T, Buechner J et al (2018) Tisagenlecleucel in children and young adults with B cell lymphoblastic leukemia. N Engl J Med 378:439–448. https://doi.org/10.1056/NEJMoa1709866.TisagenlecleucelCrossRefPubMedPubMedCentral

18.

Schuster S, Svoboda J, Chong E et al (2017) Chimeric antigen receptor T cells in refractory B cell lymphomas. N Engl J Med 377:2545–2554. https://doi.org/10.1056/NEJMoa1708566CrossRefPubMedPubMedCentral

19.

Badar T, Johnson B, Hamadani M (2020) Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma. Bone Marrow Transplant. https://doi.org/10.1038/s41409-020-01029-4CrossRefPubMed

20.

Common Terminology Criteria for Adverse Events. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf

21.

Gardner RA, Finney O, Annesley C et al (2017) Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129:3322–3331. https://doi.org/10.1182/blood-2017-02-769208CrossRefPubMedPubMedCentral

22.

Maziarz RT, Schuster SJ, Romanov VV et al (2020) Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv 4:1440–1447. https://doi.org/10.1182/bloodadvances.2019001305CrossRefPubMedPubMedCentral

23.

Signori A, Schiavetti I, Gallo F, Sormani M (2015) Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials. Eur J Neurol 22:960–966CrossRefPubMed

24.

Hakim E, Bakheit M, Bryant TN et al (2000) The social impact of multiple sclerosis—a study of 305 patients and their relatives. DisabilRehabil 22:288–293. https://doi.org/10.1080/096382800296755CrossRef

25.

Bermel R, You X, Foulds P et al (2013) Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta. Ann Neurol 73:95–103. https://doi.org/10.1002/ana.23758CrossRefPubMed

26.

Lublin FD, Reingold SC, Cohen J et al (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83:278–286. https://doi.org/10.1212/WNL.0000000000000560CrossRefPubMedPubMedCentral

27.

Rudick R, Lee JC, Simon J et al (2004) Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 56:548–555. https://doi.org/10.1002/ana.20224CrossRefPubMed

28.

Romeo M, Martinelli-Boneschi F, Rodegher M et al (2013) Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients. Eur J Neurol. https://doi.org/10.1111/ene.12119CrossRefPubMed

29.

NICE (2007) Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis. In: NICE Technol. Apprais. Guid. [TA127]. https://www.nice.org.uk/guidance/ta127

30.

Barkhof F, Rocca M, Francis G et al (2003) Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon β1a. Ann Neurol 53:718–724. https://doi.org/10.1002/ana.10551CrossRefPubMed

31.

Gallo P, Van Wijmeersch B (2015) Overview of the management of relapsing-remitting multiple sclerosis and practical recommendations. Eur J Neurol 22:14–21CrossRefPubMed

32.

Río J, Rovira A, Tintoré M et al (2008) Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. MultScler 14:479–484. https://doi.org/10.1177/1352458507085555CrossRef

33.

Park J, Rivere I, Gonen M et al (2018) Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378:449–459. https://doi.org/10.1056/NEJMoa1709919CrossRefPubMedPubMedCentral

34.

Grupp S (2018) Beginning the CAR T cell therapy revolution in the US and EU. Curr Res Transl Med 66:62–64. https://doi.org/10.1016/j.retram.2018.03.004CrossRefPubMed

35.

Cao J, Wang H, Gao W et al (2020) The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor–T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma. Cytotherapy 22:214–226. https://doi.org/10.1016/j.jcyt.2020.01.015CrossRefPubMed

36.

Alabanza L, Pegues M, Geldres C et al (2017) Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. MolTher 25:2452–2465. https://doi.org/10.1016/j.ymthe.2017.07.013CrossRef

37.

Brudno JN, Lam N, Vanasse D et al (2020) Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B cell lymphoma. Nat Med 26:270–280. https://doi.org/10.1038/s41591-019-0737-3CrossRefPubMedPubMedCentral

38.

DeAngelo D, Ghobadi A, Park J et al (2017) Clinical outcomes for the phase 2, single-arm, multicenter trial of JCAR015 in adult B-ALL (ROCKET Study). In: 32nd Annu. Meet. Pre-Conference Programs Soc. Immunother. Cancer (SITC 2017)

39.

Taraseviciute A, Tkachev V, Ponce R et al (2018) Chimeric antigen receptor T cell—mediated neurotoxicity in nonhuman primates. Cancer Discov 8:750–763. https://doi.org/10.1158/2159-8290.CD-17-1368CrossRefPubMedPubMedCentral

40.

Lee DW, Kochenderfer JN, Stetler-Stevenson M et al (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385:517–528. https://doi.org/10.1016/S0140-6736(14)61403-3.TCrossRefPubMed

41.

Norelli M, Camisa B, Barbiera G et al (2018) Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 24:739–748. https://doi.org/10.1038/s41591-018-0036-4CrossRefPubMed

42.

Rosário C, Zandman-Goddard G, Meyron-Holtz EG et al (2013) The Hyperferritinemic Syndrome: macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med 11:185. https://doi.org/10.1186/1741-7015-11-185CrossRefPubMedPubMedCentral

43.

Torre M, Solomon IH, Sutherland CL et al (2018) Neuropathology of a case with fatal CAR T cell-associated cerebral edema. J NeuropatholExpNeurol 77:877–882. https://doi.org/10.1093/jnen/nly064CrossRef

44.

Yakoub-agha I, Chabannon C, Bader P et al (2020) Management of adults and children undergoing chimeric antigen receptor T cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica 105:297–316. https://doi.org/10.3324/haematol.2019.229781CrossRefPubMedPubMedCentral

45.

Davila ML, Riviere I, Wang X et al (2014) Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6:224–225. https://doi.org/10.1126/scitranslmed.3008226CrossRef

46.

Azoulay E, Darmon M, Valade S (2020) Acute life theatening toxicity from CAR-T cell therapy. Intensive Care Med. https://doi.org/10.1007/s00134-020-06193-1CrossRefPubMedPubMedCentral

47.

Garfall AL, Lancaster E, Stadtmauer EA et al (2016) Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion Of Anti-Bcma CAR T cells (CART-BCMA) for multiple myeloma: successful treatment with cyclophosphamide. Blood 128:5702. https://doi.org/10.1182/blood.V128.22.5702.5702CrossRef

48.

Sdrimas K, Diaz M, Jose P, Lazaros FC (2020) Progressive multifocal leukoencephalopathy after CAR T therapy. Int J Hematol. https://doi.org/10.1007/s12185-020-02840-xCrossRefPubMed

49.

Hill JA, Li D, Hay KA et al (2018) Infectious complications of CD19-targeted chimeric antigen receptor—modified T cell immunotherapy. Blood 131:121–130. https://doi.org/10.1182/blood-2017-07-793760CrossRefPubMedPubMedCentral

Title: Neurological updates: neurological complications of CAR-T therapy
Authors: Emma C. Tallantyre
Nia A. Evans
Jack Parry-Jones
Matt P. G. Morgan
Ceri H. Jones
Wendy Ingram
Publication date: 01-04-2021
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 4/2021
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-020-10237-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Neurological updates: neurological complications of CAR-T therapy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2021

PolyQ-expanded ataxin-3 protein levels in peripheral blood mononuclear cells correlate with clinical parameters in SCA3: a pilot study

Guillain–Barré syndrome in the COVID-19 era: another occasional cluster?

Physical exercise improves quality of life, depressive symptoms, and cognition across chronic brain disorders: a transdiagnostic systematic review and meta-analysis of randomized controlled trials

SQSTM1 gene as a potential genetic modifier of CADASIL phenotype

18F-FDOPA-PET in pseudotumoral brain lesions

SARS-CoV-2 associated Guillain–Barré syndrome